+36 (06) 26 314 891
|
|
|
|
The stability of a drug directly affects the dose a patient receives. The dose received depends on the way the compound is metabolised or accumulated in the body. This metabolism is a key determinant of drug bioavailability. A drug that is rapidly metabolised may require multiple daily dosing or continuous infusion to maintain a concentration in the bloodstream or target organ that is sufficient to elicit a therapeutic effect. However, a slowly metabolised drug may remain in the body for long periods, potentially causing toxic build-up.
Hepatocytes contain enzymes for both phase I (oxidation, reduction and/or hydrolysis of test compound) and phase II (conjugation of test compounds or metabolites) metabolism. |
 |
Open all hours at LGC Standards’ webshop
LGC Standards’ webshop is enjoying considerable success, providing customers around the world with the convenience and flexibility of ordering in...
bővebben >>
Europe debates Stevia's 'natural' claims
Discussion continues over whether stevia compounds in food and drink products can be labelled as ‘natural’, with the weight of opinion favouring ‘f...
bővebben >>
